SNPMiner Trials by Shray Alag

SNPMiner SNPMiner Trials (Home Page)

Report for Mutation S100P

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There are 2 clinical trials

Clinical Trials

1 Pivotal Validation Study of Salivary Biomarkers for the Risk Stratification of Patients With Lesions Suspicious for Oral Squamous Cell Carcinoma

The purpose of this study is to verify the discriminatory value of previously identified salivary transcriptome and proteome markers for oral squamous cell cancer in an intended use population of patients with oral lesions suspicious for cancer.

NCT01587573 Oral Squamous Cell Carcinoma Other: saliva collection prior to clinically driven oral biopsy
MeSH:Carcinoma Carcinoma, Squamous Cell
HPO:Carcinoma Squamous cell carcinoma

Six pre-specified mRNA markers (IL1b, IL8, SAT, DUSP1, OAZ1 and S100P) are measured by polymerase chain reaction. --- S100P ---

Primary Outcomes

Description: Based on multimarker test score

Measure: Test specificity at 90% sensitivity

Time: at study completion as well as after model development following enrollment of the first 30 patents with cancer

Secondary Outcomes

Description: Based on comparison of cancer and controls

Measure: Validation of individual mRNA and protein markers

Time: After enrollment of 30 patients with cancer

Description: Based on combined sensitivity and specificity

Measure: Validation of a pre-specified multi marker model

Time: After enrollment of 30 patients with cancer

2 Pancreatic Juice Diagnosis From Duodenum

Purpose of this study is to understand the clinical feasibility of duodenal juice diagnosis to screen UICC stage II pancreatic ductal adenocarcinoma patients.

NCT01699698 Pancreatic Adenocarcinoma Other: Tumor markers

The cancer marker is S100P.. --- S100P ---

Primary Outcomes

Description: We hypothesized that there is a statistically-significant difference between two cohorts. The cancer marker is S100P.

Measure: The Concentration of the Pancreatic Cancer Markers of the Normal Cohort and UICC Stage II Pancreatic Ductal Adenocarcinoma Cohort

Time: 1year

Secondary Outcomes

Description: Based on each analyzing result of pancreatic cancer markers and corresponding final diagnosis, a receiver operating characteristic (ROC) is evaluated. A cut-off is then chosen from this ROC curve to maximize both sensitivity and specificity.1. create an ROC curve using the measured concentrations, 2. set a threshold, 3. report how many patients in each group would are exceeded the threshold. (The rate of exceeded threshold in Test subject group is sensitivity, The rate of 1-(the rate of exceeded threshold in Control group) is specificity.)

Measure: The Sensitivity and Specificity to Detect UICC Stage II Pancreatic Ductal Adenocarcinoma Among All Participants.

Time: 1 year

HPO Nodes